Unique Clinical Trial Matching Initiative Increases Patient Eligibility for Trials
The problem: Clinical research teams manually match patients one-trial-at-a-time, taking approximately 25 minutes per trial. This limits patients’ choices and clinical trial enrolment rates.
The solution: In 2023 a collaborative project between PCC and Massive Bio was initiated to find more eligible patients for biomarker-directed clinical trials by pre-screening all patients with NGS test results to all cancer trials simultaneously. The results found by this industry-leading AI technology have been accepted by ASCO for online publication. You can access the abstract on the ASCO website – abstract number e13501
Watch the video to find out more about the nearly 2-fold increase in potential patient eligibility for trials of all tumor types, and the dramatic reduction in manual effort.
Click on the video image to watch.
PCC-044
May 2024
